-- meaning the company may choose to walk away. Exact Sciences said it was pursuing an alternative that is more valuable. Earlier in the day, however, analysts appeared to doubt that idea. Oppenheimer analyst Kevin DeGeeter said the company is reporting minimal sales. -- it reported negative $700,000 in revenue during the third quarter. 
Share:  -- meaning the company may choose to walk away. <span class="company">Exact Sciences</span> said it was pursuing an alternative that is more valuable. Earlier in the day, however, analysts appeared to doubt that idea. <span class="sent"> Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said the company is reporting minimal sales. </span> -- it reported negative $700,000 in revenue during the third quarter. Tweet this 

-- meaning the company may choose to walk away. Late Monday, the board of Exact Sciences rejected Sequenom's offer of $41 million, or $1.50 per share, because it was pursuing an alternative that is more valuable. Earlier in the day, however, analysts appeared to doubt that idea. Oppenheimer analyst Kevin DeGeeter said the company is reporting minimal sales. -- it reported negative $700,000 in revenue during the third quarter. 
Share:  -- meaning the company may choose to walk away. Late Monday, the board of Exact Sciences rejected <span class="company">Sequenom</span>'s offer of $41 million, or $1.50 per share, because it was pursuing an alternative that is more valuable. Earlier in the day, however, analysts appeared to doubt that idea. <span class="sent"> Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said the company is reporting minimal sales. </span> -- it reported negative $700,000 in revenue during the third quarter. Tweet this 

-- meaning the company may choose to walk away. Late Monday, the board of Exact Sciences rejected Sequenom's offer of $41 million, or $1.50 per share, because it was pursuing an alternative that is more valuable. Earlier in the day, however, analysts appeared to doubt that idea. Oppenheimer analyst Kevin DeGeeter said the company is reporting minimal sales. -- it reported negative $700,000 in revenue during the third quarter. 
Share:  -- meaning the company may choose to walk away. Late Monday, the board of <span class="company">Exact Sciences</span> rejected Sequenom's offer of $41 million, or $1.50 per share, because it was pursuing an alternative that is more valuable. Earlier in the day, however, analysts appeared to doubt that idea. <span class="sent"> Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said the company is reporting minimal sales. </span> -- it reported negative $700,000 in revenue during the third quarter. Tweet this 

Oppenheimer analyst Kevin DeGeeter said Exact Sciences is reporting minimal sales and has a cash supply of less than six months.  
Share:  <span class="sent">Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said <span class="company">Exact Sciences</span> is reporting minimal sales and has a cash supply of less than six months. </span>..."If <span class="company">Exact</span> was a large operation, we would tread more carefully, but essentially it is nothing more than shell. Let me be clear, our proposal for $1.50 is firm and represents a fair value transaction to Sequenom." . <span class="sent"> Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said <span class="company">Exact</span> Sciences is reporting minimal sales and has a cash supply of less than six months. </span> DeGeeter said Sequenom's offer represents a "great deal" for <span class="company">Exact</span> shareholders. Tweet this 

Oppenheimer analyst Kevin DeGeeter said Exact Sciences is reporting minimal product sales, and only has enough cash to fund operations for about six months. "If they can get this done, I think it's a great deal for them," he said. Representatives of Exact Sciences could not be immediately reached for comment. 
Share:  <span class="sent">Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said <span class="company">Exact Sciences</span> is reporting minimal product sales, and only has enough cash to fund operations for about six months. </span> "If they can get this done, I think it's a great deal for them," he said. Representatives of <span class="company">Exact Sciences</span> could not be immediately reached for comment. ...It also has relationships with key doctors, which could help sell its products, he said. Lavin, who rates Sequenom at "Buy," believes that Sequenom would gain additional patent protection on its own products if it buys <span class="company">Exact</span> Sciences' intellectual property. Shares of Sequenom fell $1.15, or 5.2 percent, to $21.82. <span class="sent"> Oppenheimer analyst <span class="analyst">Kevin DeGeeter</span> said <span class="company">Exact</span> Sciences is reporting minimal product sales, and only has enough cash to fund operations for about six months. </span> "If t Tweet this